Healthy Outcome under Olanzapine Treatment in a Pregnant Woman

Julia Stingl, Anne Berghöfer, D. Bolk-Weischedel

Pharmacopsychiatry · 2000 · 82 citations · 0 references

Concepts

Abstract

Our report focuses on the case of a pregnant women with recurrent, paranoid schizophrenia. The patient was treated with Olanzapine from the 18th gestational week until delivery and during breast-feeding. No adverse events occurred during pregnancy, and the outcome was healthy. After delivery, the plasma level of olanzapine in the infant was one-third of the maternal plasma level, and during breast-feeding, it decreased to an undetectable limit.